Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SELL | P14151 | 3/20 | 0.44 |
| ▸ | SELP | P16109 | 3/20 | 0.44 |
| ▸ | SELE | P16581 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13372925 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL7591028 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL1062211 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL7582872 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL7205835 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL13362516 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL13372924 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL13372944 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL13372928 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB | |
| SCHEMBL2420891 | 1.00 | TYR (0.52) | TYRCETPTLR4ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 751 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323411-A1 | FUNCTIONALIZED BIOLOGICAL MEMBRANES WITH MODIFYING PROTEIN MOLECULES, AND METHODS OF MAKING AND USES THEREOF | McMaster University (CA) | 2024-02-21 | — | — | EP | claimed |
| EP-3602073-B1 | GENERIC PRETREATMENT REAGENTS FOR ANALYTE DETERMINATIONS | ROCHE DIAGNOSTICS GMBH (DE) | 2023-10-18 | — | — | EP | claimed |
| WO-2022217359-A1 | FUNCTIONALIZED BIOLOGICAL MEMBRANES WITH MODIFYING PROTEIN MOLECULES, AND METHODS OF MAKING AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2022-10-20 | — | — | WO | claimed |
| EP-3758744-A1 | EPSILON TOXIN FROM CLOSTRIDIUM PERFRINGENS AS A VACCINE | One Health Ventures Ltd (GB) | 2021-01-06 | — | — | EP | claimed |
| US-20200405836-A1 | EPSILON TOXIN FROM CLOSTRIDIUM PERFRINGENS AS A VACCINE | ONE HEALTH VENTURES LTD (GB) | 2020-12-31 | — | — | US | claimed |
| US-20100172845-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | US | claimed |
| US-7517968-B2 | Rapid and inexpensive method for the purification of proteorhodopsin | SYRACUSE UNIVERSITY (US) | 2009-04-14 | — | — | US | claimed |
| WO-2009002652-A9 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | UNIV TEXAS (US) | 2009-02-12 | — | — | WO | claimed |
| WO-2009002652-A2 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-31 | — | — | WO | claimed |
| US-20070020684-A1 | Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same | SMITHKLINE BEECHAM CORPORATION | 2007-01-25 | — | — | US | claimed |
| EP-1578443-A2 | COMPOSITIONS COMPRISING ANTIGEN-COMPLEXES, METHOD FOR MAKING SAME AS WELL AS METHODS OF USING THE ANTIGEN-COMPLEXES FOR VACCINATION | Crucell Holland B.V. (NL) | 2005-09-28 | — | — | EP | claimed |
| US-20050148762-A1 | Rapid and inexpensive method for the purification of proteorhodopsin | SYRACUSE UNIVERSITY | 2005-07-07 | — | — | US | claimed |
| US-20040203091-A1 | Process for synthesizing protein using cell-free protein synthesis system | RIKEN (JP) | 2004-10-14 | — | — | US | claimed |
| WO-2004045641-A2 | ANTIGEN-COMPLEXES | CRUCELL HOLLAND B.V. (NL) | 2004-06-03 | — | — | WO | claimed |
| EP-1097383-B1 | DEVICE AND METHOD FOR THE DETERMINATION OF PROTEIN DOMAIN BOUNDARIES | AFFINIUM PHARM INC (CA) | 2004-03-03 | — | — | EP | claimed |
| EP-1384778-A1 | PROCESS FOR SYNTHESIZING PROTEIN USING CELL-FREE PROTEIN SYNTHESIS SYSTEM | RIKEN (JP) | 2004-01-28 | — | — | EP | claimed |
| EP-1375517-A1 | Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020165168-A1 | USE OF SUGAR DERIVATIVES AS ANTIMICROBIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTIVE SUBSTANCES | BEIERDORF AG (DE) | 2002-11-07 | — | — | US | claimed |
| US-4871488-A | Reconstituting viral glycoproteins into large phospholipid vesicles | ALBANY MEDICAL COLLEGE OF UNION UNIVERSITY (US) | 1989-10-03 | — | — | US | claimed |
| EP-0047480-A2 | Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane | INSTITUT ARMAND FRAPPIER (CA) | 1982-03-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165168-A1 | USE OF SUGAR DERIVATIVES AS ANTIMICROBIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTIVE SUBSTANCES | TREH, MGAM, FUT6 | TYR 1638/4885CETP 1128/4885TLR4 170/4885 |
| US-20070020684-A1 | Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same | NR5A1, NR3C1, NR5A2 | TYR 4836/4885CETP 2296/4885TLR4 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.